Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.

Jassem, J; Pienkowski, T; Pluzanska, A; Jelic, S; Gorbunova, V; Mrsic-Krmpotic, Z; Berzins, J; Nagykalnai, T; Wigler, N; Renard, J; Munier, S; Weil, C

Jassem, J; Pienkowski, T; Pluzanska, A; Jelic, S; Gorbunova, V; Mrsic-Krmpotic, Z; Berzins, J; Nagykalnai, T; Wigler, N; Renard, J; Munier, S; Weil, C.

Affiliation

Jassem J; Department of Oncology and Radiotherapy, Medical University, Gdansk, Poland. jjassem@amg.gda.pl

J Clin Oncol ; 19(6): 1707-15, 2001 Mar 15.

Article in En | MEDLINE | ID: mdl-11251000

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/drug therapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Breast Neoplasms/pathology; Cyclophosphamide/administration & dosage; Disease Progression; Doxorubicin/administration & dosage; Female; Fluorouracil/administration & dosage; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel/administration & dosage; Survival Analysis; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Health context: 3_ND Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: J Clin Oncol Year: 2001 Document type: Article

Search on Google

XML

PubMed Links